Functionally biased signalling properties of 7TM receptors - Opportunities for drug development for the ghrelin receptor

British Journal of Pharmacology

Volumn 170, Issue 7, 2013, Pages 1349-1362

  Sivertsen, B ^a   Holliday, N ^b   Madsen, A N ^a   Holst, B ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

7TM receptor; biased agonism; biased signalling; ghrelin receptor; GPCR

Indexed keywords

CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; GHRELIN RECEPTOR; SIRTUIN 1; TRANSCRIPTION FACTOR FKHR; ANTIOBESITY AGENT; LIGAND;

ADIPOSE TISSUE; ANGIOGENESIS; ANXIETY; CACHEXIA; CALCIUM TRANSPORT; CARDIOVASCULAR FUNCTION; COGNITION; DOPAMINERGIC NERVE CELL; ENERGY EXPENDITURE; ENZYME ACTIVATION; FOOD INTAKE; GROWTH HORMONE RELEASE; HUMAN; INTRACELLULAR SIGNALING; LIPID STORAGE; MEMORY CONSOLIDATION; MITOCHONDRIAL RESPIRATION; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN CONFORMATION; REVIEW; WEIGHT GAIN; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; DRUG DESIGN; DRUG EFFECTS; EATING; ENERGY METABOLISM; GENETICS; METABOLISM; PATHOPHYSIOLOGY; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTI-OBESITY AGENTS; APPETITE REGULATION; DRUG DESIGN; EATING; ENERGY METABOLISM; HUMANS; LIGANDS; MOLECULAR STRUCTURE; OBESITY; PROTEIN CONFORMATION; RECEPTORS, GHRELIN; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84887814896     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12361     Document Type: Review

References (130)

1. Abizaid A, Liu ZW, Andrews ZB, Shanabrough M, Borok E, Elsworth JD, et al. (2006). Ghrelin modulates the activity and synaptic input organization of midbrain dopamine neurons while promoting appetite. J Clin Invest 116: 3229-3239.
2. Alexander SPH, Mathie A, Peters JA, (2011). Guide to receptors and channels (GRAC) 5th edition. Br J Pharmacol 164: S1-S324.
3. Andrews ZB, Liu ZW, Walllingford N, Erion DM, Borok E, Friedman JM, et al. (2008). UCP2 mediates ghrelin's action on NPY/AgRP neurons by lowering free radicals. Nature 454: 846-851.
4. Atcha Z, Chen WS, Ong AB, Wong FK, Neo A, Browne ER, et al. (2009). Cognitive enhancing effects of ghrelin receptor agonists. Psychopharmacology (Berl) 206: 415-427.
5. Bach MA, Rockwood K, Zetterberg C, Thamsborg G, Hebert R, Devogelaer JP, et al. (2004). The effects of MK-0677, an oral growth hormone secretagogue, in patients with hip fracture. J Am Geriatr Soc 52: 516-523.
6. Bayburt TH, Grinkova YG, Sligar SG, (2002). Self-assembly of discoidal phospholipid bilayer nanoparticles with membrane scaffold proteins. Nano Lett 8: 853-856.
7. Bennett KA, Langmead CJ, Wise A, Milligan G, (2009). Growth hormone secretagogues and growth hormone releasing peptides act as orthosteric super-agonists but not allosteric regulators for activation of the G protein Galpha(o1) by the ghrelin receptor. Mol Pharmacol 76: 802-811.
8. Berg KA, Maayani S, Goldfarb J, Scaramellini C, Leff P, Clarke WP, (1998). Effector pathway-dependent relative efficacy at serotonin type 2A and 2C receptors: evidence for agonist-directed trafficking of receptor stimulus. Mol Pharmacol 54: 94-104.
9. Boerrigter G, Lark MW, Whalen EJ, Soergel DG, Violin JD, Burnett JC, Jr, (2011). Cardiorenal actions of TRV120027, a novel ss-arrestin-biased ligand at the angiotensin II type I receptor, in healthy and heart failure canines: a novel therapeutic strategy for acute heart failure. Circ Heart Fail 4: 770-778.
10. Bokoch MP, Zou Y, Rasmussen SG, Liu CW, Nygaard R, Rosenbaum DM, et al. (2010). Ligand-specific regulation of the extracellular surface of a G-protein-coupled receptor. Nature 463: 108-112.
11. Bowers CY, (2001). Unnatural growth hormone-releasing peptide begets natural ghrelin. J Clin Endocrinol Metab 86: 1464-1469.
12. Bowers CY, Reynolds GA, Durham D, Barrera CM, Pezzoli SS, Thorner MO, (1990). Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone. J Clin Endocrinol Metab 70: 975-982.
13. Breit A, Buch TR, Boekhoff I, Solinski HJ, Damm E, Gudermann T, (2011). Alternative G protein coupling and biased agonism: new insights into melanocortin-4 receptor signalling. Mol Cell Endocrinol 331: 232-240.
14. Briggs DI, Andrews ZB, (2011). A recent update on the role of ghrelin in glucose homeostasis. Curr Diabetes Rev 7: 201-207.
15. Broglio F, Gottero C, Arvat E, Ghigo E, (2003a). Endocrine and non-endocrine actions of ghrelin. Horm Res 59: 109-117.
16. Broglio F, Gottero C, Benso A, Prodam F, Destefanis S, Gauna C, et al. (2003b). Effects of ghrelin on the insulin and glycemic responses to glucose, arginine, or free fatty acids load in humans. J Clin Endocrinol Metab 88: 4268-4272.
17. Broglio F, Gottero C, Prodam F, Gauna C, Muccioli G, Papotti M, et al. (2004). Non-acylated ghrelin counteracts the metabolic but not the neuroendocrine response to acylated ghrelin in humans. J Clin Endocrinol Metab 89: 3062-3065.
18. Buch TR, Heling D, Damm E, Gudermann T, Breit A, (2009). Pertussis toxin-sensitive signaling of melanocortin-4 receptors in hypothalamic GT1-7 cells defines agouti-related protein as a biased agonist. J Biol Chem 284: 26411-26420.
19. Carlini VP, Monzon ME, Varas MM, Cragnolini AB, Schioth HB, Scimonelli TN, et al. (2002). Ghrelin increases anxiety-like behavior and memory retention in rats. Biochem Biophys Res Commun 299: 739-743.
20. Chang L, Ren Y, Liu X, Li WG, Yang J, Geng B, et al. (2004). Protective effects of ghrelin on ischemia/reperfusion injury in the isolated rat heart. J Cardiovasc Pharmacol 43: 165-170.
21. Chu KM, Chow KB, Leung PK, Lau PN, Chan CB, Cheng CH, et al. (2007). Over-expression of the truncated ghrelin receptor polypeptide attenuates the constitutive activation of phosphatidylinositol-specific phospholipase C by ghrelin receptors but has no effect on ghrelin-stimulated extracellular signal-regulated kinase 1/2 activity. Int J Biochem Cell Biol 39: 752-764.
22. Costantini VJ, Vicentini E, Sabbatini FM, Valerio E, Lepore S, Tessari M, et al. (2011). GSK1614343, a novel ghrelin receptor antagonist, produces an unexpected increase of food intake and body weight in rodents and dogs. Neuroendocrinology 94: 158-168.
23. Crespo P, Xu N, Simonds WF, Gutkind JS, (1994). Ras-dependent activation of MAP kinase pathway mediated by G-protein beta gamma subunits. Nature 369: 418-420.
24. Cummings DE, Purnell JQ, Frayo RS, Schmidova K, Wisse BE, Weigle DS, (2001). A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes 50: 1714-1719.
25. Damian M, Marie J, Leyris JP, Fehrentz JA, Verdie P, Martinez J, et al. (2012). High constitutive activity is an intrinsic feature of ghrelin receptor protein: a study with a functional monomeric GHS-R1a receptor reconstituted in lipid discs. J Biol Chem 287: 3630-3641.
26. Dash PK, Karl KA, Colicos MA, Prywes R, Kandel ER, (1991). cAMP response element-binding protein is activated by Ca2+/calmodulin- as well as cAMP-dependent protein kinase. Proc Natl Acad Sci U S A 88: 5061-5065.
27. Diano S, Farr SA, Benoit SC, McNay EC, da Silva I, Horvath B, et al. (2006). Ghrelin controls hippocampal spine synapse density and memory performance. Nat Neurosci 9: 381-388.
28. Dickson SL, Egecioglu E, Landgren S, Skibicka KP, Engel JA, Jerlhag E, (2011). The role of the central ghrelin system in reward from food and chemical drugs. Mol Cell Endocrinol 340: 80-87.
29. Ehlert FJ, (2008). On the analysis of ligand-directed signaling at G protein-coupled receptors. Naunyn Schmiedebergs Arch Pharmacol 377: 549-577.
30. Ellis J, Pediani JD, Canals M, Milasta S, Milligan G, (2006). Orexin-1 receptor-cannabinoid CB1 receptor heterodimerization results in both ligand-dependent and -independent coordinated alterations of receptor localization and function. J Biol Chem 281: 38812-38824.
31. Esler WP, Rudolph J, Claus TH, Tang W, Barucci N, Brown SE, et al. (2007). Small-molecule ghrelin receptor antagonists improve glucose tolerance, suppress appetite, and promote weight loss. Endocrinology 148: 5175-5185.
32. Farrens DL, Altenbach C, Yang K, Hubbell WL, Khorana HG, (1996). Requirement of rigid-body motion of transmembrane helices for light activation of rhodopsin. Science 274: 768-770.
33. Feighner SD, Howard AD, Prendergast K, Palyha OC, Hreniuk DL, Nargund R, et al. (1998). Structural requirements for the activation of the human growth hormone secretagogue receptor by peptide and nonpeptide secretagogues. Mol Endocrinol 12: 137-145.
34. Gaborik Z, Jagadeesh G, Zhang M, Spat A, Catt KJ, Hunyady L, (2003). The role of a conserved region of the second intracellular loop in AT1 angiotensin receptor activation and signaling. Endocrinology 144: 2220-2228.
35. Ganguli SC, Park CG, Holtmann MH, Hadac EM, Kenakin TP, Miller LJ, (1998). Protean effects of a natural peptide agonist of the G protein-coupled secretin receptor demonstrated by receptor mutagenesis. J Pharmacol Exp Ther 286: 593-598.
36. Gbahou F, Rouleau A, Morisset S, Parmentier R, Crochet S, Lin JS, et al. (2003). Protean agonism at histamine H3 receptors in vitro and in vivo. Proc Natl Acad Sci U S A 100: 11086-11091.
37. Gether U, Kobilka BK, (1998). G protein-coupled receptors. II. Mechanism of agonist activation. J Biol Chem 273: 17979-17982.
38. Gnanapavan S, Kola B, Bustin SA, Morris DG, McGee P, Fairclough P, et al. (2002). The tissue distribution of the mRNA of ghrelin and subtypes of its receptor, GHS-R, in humans. J Clin Endocrinol Metab 87: 2988.
39. Goze C, Berge G, M'Kadmi C, Floquet N, Gagne D, Galleyrand JC, et al. (2010). Involvement of tryptophan W276 and of two surrounding amino acid residues in the high constitutive activity of the ghrelin receptor GHS-R1a. Eur J Pharmacol 643: 153-161.
40. Gregory KJ, Hall NE, Tobin AB, Sexton PM, Christopoulos A, (2010). Identification of orthosteric and allosteric site mutations in M2 muscarinic acetylcholine receptors that contribute to ligand-selective signaling bias. J Biol Chem 285: 7459-7474.
41. Griffin MT, Figueroa KW, Liller S, Ehlert FJ, (2007). Estimation of agonist activity at G protein-coupled receptors: analysis of M2 muscarinic receptor signaling through Gi/o,Gs, and G15. J Pharmacol Exp Ther 321: 1193-1207.
42. Guan XM, Yu H, Palyha OC, McKee KK, Feighner SD, Sirinathsinghji DJ, et al. (1997). Distribution of mRNA encoding the growth hormone secretagogue receptor in brain and peripheral tissues. Brain Res Mol Brain Res 48: 23-29.
43. Halem HA, Taylor JE, Dong JZ, Shen Y, Datta R, Abizaid A, et al. (2004). Novel analogs of ghrelin: physiological and clinical implications. Eur J Endocrinol 151 (Suppl. 1): S71-S75.
44. Hanyaloglu AC, von Zastrow M, (2008). Regulation of GPCRs by endocytic membrane trafficking and its potential implications. Annu Rev Pharmacol Toxicol 48: 537-568.
45. Harikumar KG, Wootten D, Pinon DI, Koole C, Ball AM, Furness SG, et al. (2012). Glucagon-like peptide-1 receptor dimerization differentially regulates agonist signaling but does not affect small molecule allostery. Proc Natl Acad Sci U S A 109: 18607-18612.
46. Holliday ND, Holst B, Rodionova EA, Schwartz TW, Cox HM, (2007). Importance of constitutive activity and arrestin-independent mechanisms for intracellular trafficking of the ghrelin receptor. Mol Endocrinol 21: 3100-3112.
47. Holst B, Cygankiewicz A, Jensen TH, Ankersen M, Schwartz TW, (2003). High constitutive signaling of the ghrelin receptor-identification of a potent inverse agonist. Mol Endocrinol 17: 2201-2210.
48. Holst B, Holliday ND, Bach A, Elling CE, Cox HM, Schwartz TW, (2004). Common structural basis for constitutive activity of the ghrelin receptor family. J Biol Chem 279: 53806-53817.
49. Holst B, Brandt E, Bach A, Heding A, Schwartz TW, (2005). Nonpeptide and peptide growth hormone secretagogues act both as ghrelin receptor agonist and as positive or negative allosteric modulators of ghrelin signaling. Mol Endocrinol 19: 2400-2411.
50. Holst B, Lang M, Brandt E, Bach A, Howard A, Frimurer TM, et al. (2006). Ghrelin receptor inverse agonists: identification of an active peptide core and its interaction epitopes on the receptor. Mol Pharmacol 70: 936-946.
51. Holst B, Mokrosinski J, Lang M, Brandt E, Nygaard R, Frimurer TM, et al. (2007). Identification of an efficacy switch region in the ghrelin receptor responsible for interchange between agonism and inverse agonism. J Biol Chem 282: 15799-15811.
52. Holst B, Frimurer TM, Mokrosinski J, Halkjaer T, Cullberg KB, Underwood CR, et al. (2009). Overlapping binding site for the endogenous agonist, small-molecule agonists, and ago-allosteric modulators on the ghrelin receptor. Mol Pharmacol 75: 44-59.
53. Howard AD, Feighner SD, Cully DF, Arena JP, Liberator PA, Rosenblum CI, et al. (1996). A receptor in pituitary and hypothalamus that functions in growth hormone release. Science 273: 974-977.
54. Hudson BD, Hebert TE, Kelly ME, (2010). Ligand- and heterodimer-directed signaling of the CB(1) cannabinoid receptor. Mol Pharmacol 77: 1-9.
55. Jaakola VP, Griffith MT, Hanson MA, Cherezov V, Chien EY, Lane JR, et al. (2008). The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist. Science 322: 1211-1217.
56. Jarrahian A, Watts VJ, Barker EL, (2004). D2 dopamine receptors modulate Galpha-subunit coupling of the CB1 cannabinoid receptor. J Pharmacol Exp Ther 308: 880-886.
57. Jerlhag E, Egecioglu E, Landgren S, Salome N, Heilig M, Moechars D, et al. (2009). Requirement of central ghrelin signaling for alcohol reward. Proc Natl Acad Sci U S A 106: 11318-11323.
58. Jerlhag E, Janson AC, Waters S, Engel JA, (2012). Concomitant release of ventral tegmental acetylcholine and accumbal dopamine by ghrelin in rats. PLoS ONE 7: e49557.
59. Jiang H, Betancourt L, Smith RG, (2006). Ghrelin amplifies dopamine signaling by cross talk involving formation of growth hormone secretagogue receptor/dopamine receptor subtype 1 heterodimers. Mol Endocrinol 20: 1772-1785.
60. Kahsai AW, Xiao K, Rajagopal S, Ahn S, Shukla AK, Sun J, et al. (2011). Multiple ligand-specific conformations of the beta2-adrenergic receptor. Nat Chem Biol 7: 692-700.
61. Kenakin T, (1995a). Agonist-receptor efficacy. I: mechanisms of efficacy and receptor promiscuity. Trends Pharmacol Sci 16: 188-192.
62. Kenakin T, (1995b). Agonist-receptor efficacy. II. agonist trafficking of receptor signals. Trends Pharmacol Sci 16: 232-238.
63. Kenakin T, Miller LJ, (2010). Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery. Pharmacol Rev 62: 265-304.
64. Kenakin TP, (2009). '7TM receptor allostery: putting numbers to shapeshifting proteins. Trends Pharmacol Sci 30: 460-469.
65. Kenakin TP, (2012). Biased signalling and allosteric machines: new vistas and challenges for drug discovery. Br J Pharmacol 165: 1659-1669.
66. Kern A, Albarran-Zeckler R, Walsh HE, Smith RG, (2012). Apo-ghrelin receptor forms heteromers with DRD2 in hypothalamic neurons and is essential for anorexigenic effects of DRD2 agonism. Neuron 73: 317-332.
67. Kleinau G, Mueller S, Jaeschke H, Grzesik P, Neumann S, Diehl A, et al. (2011). Defining structural and functional dimensions of the extracellular thyrotropin receptor region. J Biol Chem 286: 22622-22631.
68. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K, (1999). Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 402: 656-660.
69. Lage R, Vazquez MJ, Varela L, Saha AK, Vidal-Puig A, Nogueiras R, et al. (2010). Ghrelin effects on neuropeptides in the rat hypothalamus depend on fatty acid metabolism actions on BSX but not on gender. FASEB J 24: 2670-2679.
70. Lebon G, Warne T, Edwards PC, Bennett K, Langmead CJ, Leslie AG, et al. (2011). Agonist-bound adenosine A2A receptor structures reveal common features of GPCR activation. Nature 474: 521-525.
71. Lee SB, Shin SH, Hepler JR, Gilman AG, Rhee SG, (1993). Activation of phospholipase C-beta 2 mutants by G protein alpha q and beta gamma subunits. J Biol Chem 268: 25952-25957.
72. van der Lely AJ, Tschop M, Heiman ML, Ghigo E, (2004). Biological, physiological, pathophysiological, and pharmacological aspects of ghrelin. Endocr Rev 25: 426-457.
73. Li A, Cheng G, Zhu GH, Tarnawski AS, (2007). Ghrelin stimulates angiogenesis in human microvascular endothelial cells: implications beyond GH release. Biochem Biophys Res Commun 353: 238-243.
74. Liu JJ, Horst R, Katritch V, Stevens RC, Wuthrich K, (2012). Biased signaling pathways in beta2-adrenergic receptor characterized by 19F-NMR. Science 335: 1106-1110.
75. Lopez M, Lage R, Saha AK, Perez-Tilve D, Vazquez MJ, Varela L, et al. (2008). Hypothalamic fatty acid metabolism mediates the orexigenic action of ghrelin. Cell Metab 7: 389-399.
76. McKenney JM, Proctor JD, Harris S, Chinchili VM, (1994). A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients. JAMA 271: 672-677.
77. Martins L, Fernandez-Mallo D, Novelle MG, Vazquez MJ, Tena-Sempere M, Nogueiras R, et al. (2012). Hypothalamic mTOR signaling mediates the orexigenic action of ghrelin. PLoS ONE 7: e46923.
78. Mary S, Damian M, Louet M, Floquet N, Fehrentz JA, Marie J, et al. (2012). Ligands and signaling proteins govern the conformational landscape explored by a G protein-coupled receptor. Proc Natl Acad Sci U S A 109: 8304-8309.
79. Milligan G, (2008). A day in the life of a G protein-coupled receptor: the contribution to function of G protein-coupled receptor dimerization. Br J Pharmacol 153 (Suppl. 1): S216-S229.
80. Mokrosinski J, Frimurer TM, Sivertsen B, Schwartz TW, Holst B, (2012). Modulation of constitutive activity and signaling bias of the ghrelin receptor by conformational constraint in the second extracellular loop. J Biol Chem 287: 33488-33502.
81. Moulin A, Demange L, Berge G, Gagne D, Ryan J, Mousseaux D, et al. (2007). Toward potent ghrelin receptor ligands based on trisubstituted 1,2,4-triazole structure. 2. Synthesis and pharmacological in vitro and in vivo evaluations. J Med Chem 50: 5790-5806.
82. Mousseaux D, Le GL, Ryan J, Oiry C, Gagne D, Fehrentz JA, et al. (2006). Regulation of ERK1/2 activity by ghrelin-activated growth hormone secretagogue receptor 1A involves a PLC/PKCvarepsilon pathway. Br J Pharmacol 148: 350-365.
83. Munday MR, Campbell DG, Carling D, Hardie DG, (1988). Identification by amino acid sequencing of three major regulatory phosphorylation sites on rat acetyl-CoA carboxylase. Eur J Biochem 175: 331-338.
84. Murphy MG, Weiss S, McClung M, Schnitzer T, Cerchio K, Connor J, et al. (2001). Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women. J Clin Endocrinol Metab 86: 1116-1125.
85. Nagaya N, Uematsu M, Kojima M, Date Y, Nakazato M, Okumura H, et al. (2001). Elevated circulating level of ghrelin in cachexia associated with chronic heart failure: relationships between ghrelin and anabolic/catabolic factors. Circulation 104: 2034-2038.
86. Nickolls SA, Fleck B, Hoare SR, Maki RA, (2005). Functional selectivity of melanocortin 4 receptor peptide and nonpeptide agonists: evidence for ligand-specific conformational states. J Pharmacol Exp Ther 313: 1281-1288.
87. Nobles KN, Xiao K, Ahn S, Shukla AK, Lam CM, Rajagopal S, et al. (2011). Distinct phosphorylation sites on the beta(2)-adrenergic receptor establish a barcode that encodes differential functions of beta-arrestin. Sci Signal 4: ra51.
88. O'Hayre M, Salanga CL, Handel TM, Hamel DJ, (2010). Emerging concepts and approaches for chemokine-receptor drug discovery. Expert Opin Drug Discov 5: 1109-1122.
89. Palus S, Schur R, Akashi YJ, Bockmeyer B, Datta R, Halem H, et al. (2011). Ghrelin and its analogues, BIM-28131 and BIM-28125, improve body weight and regulate the expression of MuRF-1 and MAFbx in a rat heart failure model. PLoS ONE 6: e26865.
90. Papotti M, Ghe C, Cassoni P, Catapano F, Deghenghi R, Ghigo E, et al. (2000). Growth hormone secretagogue binding sites in peripheral human tissues. J Clin Endocrinol Metab 85: 3803-3807.
91. Park JG, Muise A, He GP, Kim SW, Ro HS, (1999). Transcriptional regulation by the gamma5 subunit of a heterotrimeric G protein during adipogenesis. EMBO J 18: 4004-4012.
92. Pin JP, Kniazeff J, Liu J, Binet V, Goudet C, Rondard P, et al. (2005). Allosteric functioning of dimeric class C G-protein-coupled receptors. FEBS J 272: 2947-2955.
93. Rahmeh R, Damian M, Cottet M, Orcel H, Mendre C, Durroux T, et al. (2012). Structural insights into biased G protein-coupled receptor signaling revealed by fluorescence spectroscopy. Proc Natl Acad Sci U S A 109: 6733-6738.
94. Rask-Andersen M, Almen MS, Schioth HB, (2011). Trends in the exploitation of novel drug targets. Nat Rev Drug Discov 10: 579-590.
95. Rasmussen SG, Choi HJ, Rosenbaum DM, Kobilka TS, Thian FS, Edwards PC, et al. (2007). Crystal structure of the human beta2 adrenergic G-protein-coupled receptor. Nature 450: 383-387.
96. Rasmussen SG, DeVree BT, Zou Y, Kruse AC, Chung KY, Kobilka TS, et al. (2011). Crystal structure of the beta2 adrenergic receptor-Gs protein complex. Nature 477: 549-555.
97. Rediger A, Piechowski CL, Habegger K, Gruters A, Krude H, Tschop MH, et al. (2012). MC4R dimerization in the paraventricular nucleus and GHSR/MC3R heterodimerization in the arcuate nucleus: is there relevance for body weight regulation? Neuroendocrinology 95: 277-288.
98. Reiner S, Ambrosio M, Hoffmann C, Lohse MJ, (2010). Differential signaling of the endogenous agonists at the beta2-adrenergic receptor. J Biol Chem 285: 36188-36198.
99. Richman JG, Kanemitsu-Parks M, Gaidarov I, Cameron JS, Griffin P, Zheng H, et al. (2007). Nicotinic acid receptor agonists differentially activate downstream effectors. J Biol Chem 282: 18028-18036.
100. Rudolph J, Esler WP, O'Connor S, Coish PD, Wickens PL, Brands M, et al. (2007). Quinazolinone derivatives as orally available ghrelin receptor antagonists for the treatment of diabetes and obesity. J Med Chem 50: 5202-5216.
101. Sabbatini FM, Di FR, Corsi M, Cavanni P, Bromidge SM, St-Denis Y, et al. (2010). Discovery process and characterization of novel carbohydrazide derivatives as potent and selective GHSR1a antagonists. ChemMedChem 5: 1450-1455.
102. Sakkou M, Wiedmer P, Anlag K, Hamm A, Seuntjens E, Ettwiller L, et al. (2007). A role for brain-specific homeobox factor Bsx in the control of hyperphagia and locomotory behavior. Cell Metab 5: 450-463.
103. Sato T, Nakashima Y, Nakamura Y, Ida T, Kojima M, (2011). Continuous antagonism of the ghrelin receptor results in early induction of salt-sensitive hypertension. J Mol Neurosci 43: 193-199.
104. Schellekens H, van Oeffelen WE, Dinan TG, Cryan JF, (2013). Promiscuous dimerization of the growth hormone secretagogue receptor (GHS-R1a) attenuates ghrelin-mediated signaling. J Biol Chem 288: 181-191.
105. Schwartz TW, Sakmar TP, (2011). Structural biology: snapshot of a signalling complex. Nature 477: 540-541.
106. Seta K, Nanamori M, Modrall JG, Neubig RR, Sadoshima J, (2002). AT1 receptor mutant lacking heterotrimeric G protein coupling activates the Src-Ras-ERK pathway without nuclear translocation of ERKs. J Biol Chem 277: 9268-9277.
107. Sheikh SP, Zvyaga TA, Lichtarge O, Sakmar TP, Bourne HR, (1996). Rhodopsin activation blocked by metal-ion-binding sites linking transmembrane helices C and F. Nature 383: 347-350.
108. Sivertsen B, Lang M, Frimurer TM, Holliday ND, Bach A, Els S, et al. (2011). Unique interaction pattern for a functionally biased ghrelin receptor agonist. J Biol Chem 286: 20845-20860.
109. Smith RG, Van der Ploeg LH, Howard AD, Feighner SD, Cheng K, Hickey GJ, et al. (1997). Peptidomimetic regulation of growth hormone secretion. Endocr Rev 18: 621-645.
110. Spiegelberg BD, Hamm HE, (2005). G betagamma binds histone deacetylase 5 (HDAC5) and inhibits its transcriptional co-repression activity. J Biol Chem 280: 41769-41776.
111. Stallaert W, Christopoulos A, Bouvier M, (2011). Ligand functional selectivity and quantitative pharmacology at G protein-coupled receptors. Expert Opin Drug Discov 6: 811-825.
112. Steen A, Thiele S, Guo D, Hansen LS, Frimurer TM, Rosenkilde MM, (2013). Biased and constitutive signaling in the CC-chemokine receptor CCR5 by manipulating the interface between transmembrane helices 6 and 7. J Biol Chem 288: 12511-12521.
113. Stehno-Bittel L, Krapivinsky G, Krapivinsky L, Perez-Terzic C, Clapham DE, (1995). The G protein beta gamma subunit transduces the muscarinic receptor signal for Ca2+ release in Xenopus oocytes. J Biol Chem 270: 30068-30074.
114. Stevanovic D, Janjetovic K, Misirkic M, Vucicevic L, Sumarac-Dumanovic M, Micic D, et al. (2012). Intracerebroventricular administration of metformin inhibits ghrelin-induced Hypothalamic AMP-kinase signalling and food intake. Neuroendocrinology 96: 24-31.
115. Swaminath G, Deupi X, Lee TW, Zhu W, Thian FS, Kobilka TS, et al. (2005). Probing the beta2 adrenoceptor binding site with catechol reveals differences in binding and activation by agonists and partial agonists. J Biol Chem 280: 22165-22171.
116. Tang WJ, Gilman AG, (1991). Type-specific regulation of adenylyl cyclase by G protein beta gamma subunits. Science 254: 1500-1503.
117. Tschop M, Smiley DL, Heiman ML, (2000). Ghrelin induces adiposity in rodents. Nature 407: 908-913.
118. Tschop M, Weyer C, Tataranni PA, Devanarayan V, Ravussin E, Heiman ML, (2001). Circulating ghrelin levels are decreased in human obesity. Diabetes 50: 707-709.
119. Ulloa-Aguirre A, Crepieux P, Poupon A, Maurel MC, Reiter E, (2011). Novel pathways in gonadotropin receptor signaling and biased agonism. Rev Endocr Metab Disord 12: 259-274.
120. Van der Ploeg LH, Martin WJ, Howard AD, Nargund RP, Austin CP, Guan X, et al. (2002). A role for the melanocortin 4 receptor in sexual function. Proc Natl Acad Sci U S A 99: 11381-11386.
121. Velasquez DA, Martinez G, Romero A, Vazquez MJ, Boit KD, Dopeso-Reyes IG, et al. (2011). The central Sirtuin 1/p53 pathway is essential for the orexigenic action of ghrelin. Diabetes 60: 1177-1185.
122. Violin JD, Lefkowitz RJ, (2007). Beta-arrestin-biased ligands at seven-transmembrane receptors. Trends Pharmacol Sci 28: 416-422.
123. Violin JD, DeWire SM, Yamashita D, Rominger DH, Nguyen L, Schiller K, et al. (2010). Selectively engaging beta-arrestins at the angiotensin II type 1 receptor reduces blood pressure and increases cardiac performance. J Pharmacol Exp Ther 335: 572-579.
124. Wei H, Ahn S, Shenoy SK, Karnik SS, Hunyady L, Luttrell LM, et al. (2003). Independent beta-arrestin 2 and G protein-mediated pathways for angiotensin II activation of extracellular signal-regulated kinases 1 and 2. Proc Natl Acad Sci U S A 100: 10782-10787.
125. Xin Z, Serby MD, Zhao H, Kosogof C, Szczepankiewicz BG, Liu M, et al. (2006). Discovery and pharmacological evaluation of growth hormone secretagogue receptor antagonists. J Med Chem 49: 4459-4469.
126. Yang C, Wang Y, Liu H, Li N, Sun Y, Liu Z, et al. (2012). Ghrelin protects H9c2 cardiomyocytes from angiotensin II-induced apoptosis through the endoplasmic reticulum stress pathway. J Cardiovasc Pharmacol 59: 465-471.
127. Ye S, Zaitseva E, Caltabiano G, Schertler GF, Sakmar TP, Deupi X, et al. (2010). Tracking G-protein-coupled receptor activation using genetically encoded infrared probes. Nature 464: 1386-1389.
128. Zhang J, Ferguson SS, Barak LS, Bodduluri SR, Laporte SA, Law PY, et al. (1998). Role for G protein-coupled receptor kinase in agonist-specific regulation of mu-opioid receptor responsiveness. Proc Natl Acad Sci U S A 95: 7157-7162.
129. Zhang S, Coso OA, Lee C, Gutkind JS, Simonds WF, (1996). Selective activation of effector pathways by brain-specific G protein beta5. J Biol Chem 271: 33575-33579.
130. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, et al. (2001). Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 108: 1167-1174.